Crystalide is a trademark cosmetic ingredient containing palmitoyl tetrapeptide-10 in a properly formulated carrier system. It is not the name of an isolated natural protein. The supplier binds this ingredient to improve the quality of the skin’s surface, radiance, and hydration.[1]
The interpretation of the available evidence requires precision. The publicly available materials include the results of cosmetic studies in humans presented by the supplier and laboratory experiments described in the patent documentation. These are sources of scientific information, but they should not be presented as an extensive collection of independently replicated clinical studies.
The main distinction is the separation of the peptide itself, the commercial ingredient of Crystalide, and the finished cream or serum.
What is Crystalide? Names, synonyms and identity
The name Crystalide is of particular importance in scientific publications because the same trade name may appear in supplier catalogs, patents, on cosmetic packaging, and in ingredient databases.
These sources can describe different levels of the supply chain.
The supplier's declaration can specify the composition of the offered mixture, whereas the patent can define the family of possible peptides and present examples of preferred structures.
None of these documents must reveal the full quantitative composition of the consumer cream.
Before comparing the results, it is therefore necessary to determine which material was actually tested.
A useful entry in the evidence database should separate the source of the declaration, the experimental material, and the measured endpoint.
For example, a study brochure may correctly present a laboratory observation, but this does not prove that the observed mechanism explains the improvement observed in the study of volunteers.
Treating these two observations as a single confirmed causal sequence would mean adding a conclusion whose findings were not independently verified.
Crystalide is the trade name of Sederma/Croda for a cosmetic ingredient containing a peptide.
The current INCI declaration identifies this peptide as palmitoyl tetrapeptide-10.
The patent of Sederma clearly links Crystalide to the Pal-KTFK peptide in a properly developed delivery system.[1][2]
The abbreviation Pal-KTFK stands for palmitoylated peptide with the sequence lysine–tryosine–phenylalanine–lysine.
It describes the peptide component, not all the substances present in the commercial mixture.
Therefore, the claim regarding pure palmitoyl tetrapeptide-10 is not automatically true for Crystalide. This relationship also works in the other direction.
Crystalide should not be confused with alpha-crystallin.
Alpha-crystallin is a protein discussed in the context of the proposed biological mechanism. It does not constitute the chemical identity of a peptide.
The similarity of the names does not mean that the cosmetic ingredient is a preparation containing this protein.
When searching for research, the trade name alone may not be enough to find all the relevant documents.
Searching for the INCI name, the sequence abbreviation, the supplier documentation, and related patents helps to determine the identity.
The publication mentioning the crystaline, but not testing the peptide, however, constitutes only contextual evidence and should not be counted as a study of Crystalide.
How is Crystalide classified? Peptide, protein, mixture, or other substance?
In chemical terminology, the KTFK sequence includes four amino acid residues.
The attached palmitoyl group changes the molecule's properties compared to the unmodified tetrapeptide.
This means that the compound is a lipid-modified peptide, and not just a mixture of four free amino acids.
Emulsifiers and lipids listed in the composition, however, perform a formulary function and do not constitute an extension of the peptide chain.
This distinction also prevents confusion between the statements „contains a peptide” and „is a peptide”.
The first can properly describe a multi-component cosmetic ingredient.
The second suggests a single, chemically defined substance and may mislead individuals seeking a summary pattern, peptide concentration, or pharmacological characteristics.
In the case of cosmetic claims, this is important because the physical properties of the mixture and its effect on the skin's appearance can depend on both the carrier and the mentioned peptide.
The peptide component of Crystalide is a modified tetrapeptide, whereas the supplied Crystalide raw material is a mixture.
The current declaration includes water, caprylic/capric triglycerides, cetyl palmitate, sorbitan stearate, polysorbate 80, hydrogenated lecithin, and palmitoyl tetrapeptide-10.[1]
Tetrapeptide contains four amino acid residues.
Palmitic modification adds a lipid-derived group, but it does not convert the molecule into a large protein or a hormone.
The carrier components are additional substances, not the next amino acids in the peptide sequence.
| Level of identity | What does it mean | Required evidence |
|---|---|---|
| Pal-KTFK / palmitoyl tetrapeptide-10 | Modified peptide | Confirmation of the analytical structure and identity |
| Crystalide component | The delivered formulation containing the peptide | Current composition and specifications |
| Ready cream or serum | Consumer product containing the ingredient | Stability, tolerance, and effectiveness of a specific formulation |
| Alpha-crystalline | Protein analyzed as a biological target or response marker | Mechanistic measurements, not similarity of names |
This classification is important when interpreting percentage declarations.
The share of the commercial component of Crystalide in the cream is not equal to the share of the pure peptide.
This is also significant when the seller describes the finished formulation simply as „Crystalide peptide”, omitting a significant portion of the actual material.
The structure and composition of Crystalide – what has been established?
The structural identifier should be interpreted in conjunction with chemical modifications.
The final OH group in Pal-KTFK-OH indicates a free carboxyl group at the C-terminus in the preferred patent example.
It should not be replaced without justification with an endomerated amide.
Similarly, the palmitoylated sequence is not equivalent to a KTFK devoid of a lipid group.
Such changes can affect solubility, interactions with formulation components, and experimental behavior, even if the amino acid sequence looks similar.
In analytical comparisons, researchers should best document the identity and quantity of the peptide, the associated impurities, the formulation matrix, and stability under appropriate conditions.
These are issues distinct from the consumer concept of skin radiance.
The manufacturer's description is useful for determining the declared composition, but it does not constitute an independent examination of each batch of retail serum containing the component's name.
The related patent identifies Pal-KTFK-OH as the preferred peptide, with palmitic acid at the N-terminus and a free carboxyl group at the C-terminus.[3]
These details are more informative than the broad term „signaling peptide,” but they still only describe one component of the formulation.
The carrier of the commercial component is part of the delivery concept.
Its presence means that the behavior of the preparation cannot be predicted solely based on the sequence of the isolated peptide.
At the same time, the description of the delivery system does not replace measurements that show where the peptide is going and what amount remains available in a specific finished product.
Crystalide as a mixture does not have a single aggregate pattern or a single molecular mass.
The pattern assigned to palmitoyl tetrapeptide-10 should be clearly indicated as referring to this component.
Otherwise, the chemical specification of a single molecule may be mistakenly considered to be a complete description of the trademarked raw material.
Croda also provides a separate resource regarding the test cream used in the clinical trial. [4]
Distinction is important: the raw material and the finished test cream are not identical, and the results obtained for the latter should be interpreted in the context of the entire formulation.
Research on Crystalide – evidence in humans, animals and in the laboratory
Evidence can be organized on three levels.
The first includes analytical and formulation documentation identifying the research material.
The second concerns cellular and tissue experiments that analyze possible biological responses.
The third category includes cosmetic tests on humans that measure the appearance or surface properties of the skin under specific conditions.
The strength of the claim increases when these levels are linked by a well-described experiment, rather than a narrative that assumes that every intermediate step has been confirmed.
Numerical results should retain information about the size of groups and the conditions of comparison.
The result obtained in 26 volunteers is not automatically confirmed in a separate group of 29 people.
The percentage change relative to the starting value is also not equivalent to the difference between the active preparation and the placebo.
Maintaining these details improves the informational value of the results and prevents overstating the degree of their independent confirmation.
Results of cosmetic testing on humans presented by the supplier
Croda reports on a six-week assessment of skin appearance in 26 volunteers with phototypes I–III.
An improvement of 33.5% was reported in the CLCT skin appearance index compared to the baseline value.
The same page describes separate assessments of keratinocytes and hydration involving 29 and 25 volunteers respectively.[1]
These numbers should not be summed up and it should not be claimed that the participation of 80 different people has been confirmed.
The individual assessments could have included partially overlapping groups, and the public summary does not justify such a total number.
Similarly, the percentage change in the assessment index does not mean the percentage of repaired skin or the percentage reduction in aging.
The patent distinguishes a single blinded, controlled placebo study comparing opposite areas of skin in 29 women from a separate study of skin appearance in 26 women, evaluated against baseline values.[3]
Distinguishing is important: the percentage result regarding skin appearance should not be presented as a result of treatment adjusted for placebo.
The comparison with the baseline value answers the question of whether the result has changed after the product was used.
A controlled comparison answers the question of whether the change was greater than in the comparison condition.
Both approaches can be informative, but they do not provide the same level of causal inference.
Laboratory studies and tissue models
The patent describes experiments on keratinocytes, reconstructed skin and skin explants.
Among other things, differences in the stratum corneum and parameters related to alpha-crystallin were analyzed.[3]
Human cell and explantations are not the subject of clinical trials in humans.
They help analyze the biological plausibility of the mechanism, but leave unanswered questions regarding the delivery of the substance, the durability of the effect, and the effectiveness under real-world conditions of use.
A targeted search in PubMed for the names Crystalide and palmitoyl tetrapeptide-10 did not yield any records.
This does not mean that no experiments exist, because the supplier's documentation and patents confirm that they were conducted.
However, this means that no direct evidence base indexed in PubMed was identified under the searched names.
The review did not directly identify an appropriate study of the efficacy of the trademarked ingredient Crystalide in animals.
Non-clinical studies on crystaline biology involving animals should not be classified as studies on this cosmetic ingredient.
Independent studies helpful in interpreting the results
The original study on skin radiance measurement showed that repeatability and reproducibility depended on the parameter being measured, the measurement location, and the person performing the assessment.[5]
This supports the need for careful standardization of cosmetic evaluations, but does not confirm the effectiveness of Crystalide itself.
In another experimental study, it was shown that a change in skin hydration affects its optical properties and apparent transparency.[6]
This provides an alternative or additional explanation for some changes in appearance after the use of a moisturizing product.
It does not rule out the activity of the peptide, but indicates the importance of comparing it with a matched carrier before attributing the entire effect to this activity.
Mechanism of action analyzed in the Crystalide studies
The proposed routes should be considered as hypotheses with varying degrees of experimental support.
The change in the concentration of the differentiation-related protein in the laboratory preparation confirms the response under the given conditions.
However, it does not determine the amount of peptide that passes through intact human skin, which cells come into contact with, nor whether the response is necessary to obtain the observed cosmetic effect.
These relationships require separate measurements.
The distinction between biological and optical explanations is particularly important in skin appearance studies.
Moistening can affect the scattering of light and the visibility of surface irregularities without the need to alter the structure of the deeper tissues.
In turn, the molecular response may occur without any visible difference.
A reliable description should take into account both possibilities and not assume that the photograph confirms the mechanism.
Skin differentiation and protein markers
The developmental justification concerns the maturation of epidermal cells and the appearance of the skin surface.
The patent experiments describe the effects on markers related to differentiation and alpha-crystallin.
The provider’s materials combine these observations with a smoother and more uniform appearance of the skin. [3]
The increase in the marker level is a biological observation, not evidence that the same pathway caused a noticeable change in each volunteer.
Establishing such a relationship would require evidence linking exposure, molecular response, and an appropriate endpoint in humans, rather than treating them as equivalent results.
What does the term „epigenetic” mean in this context?
The discussion of epigenetic mechanisms in the patent includes ANCR, long non-coding RNA associated with skin differentiation.
A reduction in its expression in cultured keratinocytes has been described.[3]
This is not evidence that the cream changes the DNA sequence, permanently reprogrammes the skin, or reverses biological aging.
Changes in gene expression and epigenetic mechanisms are related concepts, but they do not mean identical measurements.
The result regarding a specific RNA should be described precisely.
Broad terms such as „cellular reset” or „genetic rejuvenation” would require significantly more evidence and are not justified by the materials reviewed.
Moisturizing and the visual appearance of the skin
The appearance of the skin depends partly on the way light interacts with the surface and deeper-lying tissues.
The moisture study showed that moisture alone can change these optical properties.[6]
Therefore, the improvement in radiance or translucency does not unequivocally identify the mechanism specific to the peptide.
This does not mean that the changes in appearance associated with hydration are insignificant.
However, it means that the result should be called exactly.
A person may observe a cosmetic improvement, but the observation alone does not confirm structural remodeling, disease treatment, or a change in biological age.
Limitations of scientific evidence regarding Crystalide
Several types of uncertainty should be presented separately.
Internal accuracy it concerns whether the comparison in the study allows assigning the measured change to the tested formulation.
External accuracy it concerns whether the result applies to other skin tones, age groups, environmental conditions, or finished products.
Mechanistic accuracy it concerns whether the proposed biological explanation actually accounts for the observed change.
The study may provide useful information in one area, leaving the rest unresolved.
Commercial funding is important for transparency, but the fundamental questions remain methodological.
Was the endpoint chosen before the study began?
Were the measurements performed under blinding conditions?
Did the control formulation correspond to the carrier of the active preparation?
Were all eligible participants included in the analysis?
When these details are not publicly available, the correct term is „not determined based on the available report,” rather than assuming that the procedures were performed or that they were not carried out.
Public reporting and independence
The identified direct evidence comes mainly from the supplier or from patent documentation.
Original reports are useful, but no independent, peer-reviewed replication has been identified in the searched sources.
Repeating information on distributor websites and in product descriptions does not create additional independent experiments.
Not all the details of the research can be reproduced from the public summaries.
Allocation methods, full analysis plans, exclusions, missing data, and reporting of adverse events are important when assessing the strength of cosmetic claims.
The patent also has a different purpose and evaluation process than the article describing the clinical trials.
Population and endpoint limitations
Skin-type-specific testing does not confirm equivalent results across all skin tones.
The results obtained in selected adult volunteers cannot be automatically generalized to individuals with inflammatory skin diseases or significant hypersensitivity.
Brightness, hydration, surface texture, the size of the corneocytes and wrinkles are separate endpoints.
A positive result for one should not be used to declare that the quality of the skin is perfect in every other respect.
Even a statistically significant change in scoring requires interpretation in terms of visibility, magnitude of the effect, and significance for the intended user.
Formulation and durability of the effects
A product containing the same INCI peptide may have a different concentration, carrier, or combination of ingredients.
The evidence regarding the tested formulation does not confirm the effectiveness of any serum that uses the trade name.
A six-week observation also does not establish the durability of the results after discontinuation of use.
Tolerance
A cosmetic peptide is not automatically free from the risk of irritation.
A small group in the efficacy study cannot rule out rare reactions.
An evaluation of the finished formulation remains necessary, because exposure depends on the entire product.
The absence of a reported problem in the short public summary does not constitute proof of universal safety.
Frequently asked questions about Crystalide
1. Does Crystalide mean one defined substance?
No. The name refers to the branded ingredient containing the peptide, not to a single isolated molecule. The peptide component can be identified separately, but the commercial carrier is also part of the material. The precise declaration should specify whether it refers to a peptide, a commercial mixture, or a finished product.
The brand name may remain unchanged, while the specifications of the supplier and the formulations of ready-made products change over time. Therefore, where possible, the date of the composition declaration should be provided, and the specific retail product should be evaluated based on its current list of ingredients. Differentiation is particularly important when comparing an older patent example with a newer entry in the trade catalog.
2. What do the available studies on Crystalide confirm?
They provide the cosmetic results presented by the supplier and mechanistic observations revealed in patents. They do not confirm universal skin rejuvenation or the equivalent effectiveness of all products containing a peptide. It is more appropriate to describe them as evidence regarding specific formulations, with limited independent clinical confirmation.
The available materials better document the proposed component identity and preliminary cosmetic signals than the universal clinical effect. The improvement reported by the supplier is an observation worth describing, but public data do not provide the same certainty as the numerous independent, blinded, and fully described studies using comparable endpoints.
3. Is Crystalide the same as palmitoyl tetrapeptide-10?
Palmitoyl tetrapeptide-10 is a peptide component, whereas Crystalide is a commercial formulation containing this peptide. Differentiation is important for the concentration, delivery, and interpretation of studies. Evidence for one level does not automatically indicate that all materials at a different level behave identically.
It is also a matter of attributing effects. The commercial component includes substances related to delivery, and the finished product may contain many additional ingredients. If the consumer notices a change in appearance, the mere observation does not identify the substance responsible for the effect. Testing the peptide itself, the carrier, and their combination would help answer a more detailed mechanistic question.
4. What does Pal-KTFK mean?
It is an abbreviation meaning a palmitoylated peptide containing lysine, threonine, phenylalanine, and lysine. The supplier's patent materials link this sequence to the Crystalide component.[2] The designation identifies the peptide portion, not the full composition or the guaranteed efficacy of the cosmetic.
The one-liter sequence record is convenient for researchers, but it omits information about the carrier and the other components. The complete material description should specify the chemistry of the terminal groups and whether the peptide was tested separately or in a formulation. Otherwise, two experiments may appear comparable in the database even though significantly different preparations were used.
5. Does tetrapeptide-10 contain ten amino acids?
No. The term „tetrapeptide” means a peptide composed of four amino acid residues. The number in the name of the cosmetic ingredient does not indicate the length of the chain. Confusing the identifier with the number of residues leads to a misinterpretation of the chemical structure. The actual structural basis for interpretation is the actual sequence and modifications.
INCI numbers function as part of the component identifier, rather than as a direct number of amino acid residues. This sequence is the appropriate evidence of the peptide's length. This avoids the common mistake of assuming that a longer name means a longer or more potent peptide.
6. Does Crystalide consist of alpha-crystalline material?
No. Alpha-crystallin is discussed as a marker of biological response or a proposed target, not the identity of the peptide component. The substance that alters the measurement of a specific protein does not therefore become a preparation containing that protein. Maintaining this distinction prevents the mechanistic claim from being transformed into an untrue statement of composition.
The measurements related to alpha-crystallin refer to the possible cellular response in the described experiments, and not to the protein added as the main active peptide. Even if the experiment detects a change in the protein level, this does not mean that the cosmetic is delivering this protein to the skin or that the change is responsible for all the visible results.
7. Does the percentage of Crystalide mean the same amount of pure peptide?
No. Unless otherwise specified, the percentage refers to the commercial blend of ingredients. The amount of actual peptide depends on the quantitative composition of the raw material. The percentage value given in the product declaration should therefore not be converted into peptide content without appropriate specification.
For example, a ready-made cream containing a certain proportion of commercial raw material also contains its carrier. Without a quantitative specification of the peptide, the amount of palmitoyl tetrapeptide-10 cannot be derived solely from the percentage on the label. A numerical estimate without this information would create an apparent precision.
8. Was the reported improvement in skin appearance compared to a placebo?
The reported percentage change in skin appearance was measured relative to the baseline value. The patent describes this assessment separately from the placebo-controlled group. [3] Reporting the result as a percentage of the Crystalide advantage over placebo would change its significance and inflate the range of confirmed effects.
The distinction affects the strength of the causal interpretation. The improvement over the baseline value may reflect the action of the test cream, changes in hydration, environmental conditions, or variability in measurements. Comparing it to a matched placebo or control helps to separate these influences. Therefore, the value of 33.5% should remain associated with the actual CLCT index and the comparison to the baseline value.
9. Does the change in the skin appearance index of 33.5% mean that the skin has become 33.5% years younger?
No. This is a change in a specific cosmetic point index, not a measure of biological age. Different scales quantify different characteristics and cannot be converted into an inverse of aging. The result should retain the name of the endpoint, rather than becoming a broader percentage value of rejuvenation.
The point score is constructed from selected measurement characteristics and may not have a direct translation into age years, cellular regeneration, or permanent skin remodeling. The scientific summaries should provide the name of the index and specify whether the percentage represents a relative change, an absolute difference in scoring, or an adjusted estimate compared to placebo.
10. Does the improvement in hydration indicate a specific effect of the peptide?
No. Humectants can independently change the moisture content and the appearance of the skin. Independent experimental studies confirm the effect of moisture on optical properties.[6] Before attributing the entire result to a peptide instead of the entire formulation, a proper comparison with the carrier is necessary.
The physical properties of the cream can change the skin’s appearance even when the peptide does not have a measurable independent effect. This does not prove Crystalide ineffective, but it shows why proper control is necessary. Assigning a mechanism is a separate question from whether users notice an improvement after using the entire formulation.
11. Does epigenetic activity mean permanent modification of DNA?
No. The expression result does not confirm a change in DNA sequence or a lasting effect. The mechanism described in the patent is much narrower than the claim of genetic rejuvenation. The durability and clinical consequences would require separate evidence, not inference from the terminology alone.
The reported change in the expression of ANCR in cultured cells is a specific molecular observation. It does not show DNA editing, heritable change, or a lasting biological effect in human skin. Long-term durability would require follow-up measurements after the exposure ends, and the molecular pathway – additional experiments confirming its causal role.
12. Are human skin cell studies clinical trials?
No. Isolated cells and reconstructed skin are laboratory models, even if they are derived from human tissue. They can reveal biological responses under controlled conditions, but they do not replicate exposure and tolerance at the whole-organism level. Claims about appearance require appropriate human studies in addition to mechanistic experiments.
Cell cultures and skin explants allow for the controlled analysis of selected biological processes, but they cannot fully replicate the circulation, behaviors, environmental exposure, and complexity of human skin. Their value lies in the mechanisms. Claims of apparent cosmetic efficacy or tolerance require appropriately designed human studies using a proper formulated product.
13. Is it possible to sum up all the reported numbers of participants?
No, unless the reports confirm that the groups are distinct. Different endpoints can be measured among partially overlapping participants or within subgroups of one panel. Summing without such information can inflate the size of the evidence base, therefore the number should be attributed to specific assessments.
Even when several counts are reported, it must be checked that they represent separate cohorts, overlapping subgroups, or repeated measurements among the same volunteers. Counting each endpoint as a new participant may inflate the range of evidence. A careful review maintains each reported count without inflating the total value.
14. Does the skin radiance study confirm the reduction of wrinkles?
No. Luminosity and wrinkles are separate parameters. Improvements in light reflection, hydration, or surface uniformity may occur without a demonstrated reduction in wrinkle depth. The claim of wrinkle reduction requires testing designed to measure this result, and not the use of the general effect of improving skin brightness.
The depth of wrinkles, surface roughness, reflectance and radiance can be measured using various instruments and scales. A product can affect one parameter without changing the others. If a reduction of wrinkles is claimed, it should be supported by measurements specific to wrinkles and an appropriate comparator, rather than inferred from an improvement in the skin appearance index.
15. Can the results be applied to every skin tone?
No. The studied population limits the scope of the conclusions. The selected range of phototypes does not confirm equal effects or the same effectiveness of measurement methods across all skin tones. Wider, appropriately analyzed studies would be needed before formulating universal statements.
Skin tone can influence both the biological appearance of skin characteristics and the performance of optical measurement methods. The range of phototypes in this group is therefore important. Studies involving more diverse populations and reporting results in appropriate subgroups would help determine whether the observed changes can be generalized beyond the study participants.
16. Does the patent constitute independent confirmation of effectiveness?
No. A patent is a technical document related to an invention. It may contain useful experiments, but it does not provide for independent replication of the supplier’s claims. Patent results should be clearly cited and evaluated alongside the independently conducted clinical studies, rather than being treated as a substitute for them.
The patent study focuses on the requirements regarding the claimed invention, rather than reproducing a clinical study or confirming any cosmetic result. The patent may provide information about the sequences, proposed mechanisms, and disclosed experiments. However, it should not be described as a second independent study when it presents work from the same development program.
17. Which studies would most strengthen the claims regarding Crystalide?
Independent, fully described studies of validated ready-made formulations would be of greatest value. They should use calibrated controls, include appropriate skin tones, measure the declared results, and assess tolerance and durability. Such studies would help distinguish the reproducible contribution of the peptide from the overall moisturizing effects and the results specific to a particular experiment.
A particularly useful project would compare the ready-made formulation with a visually matched carrier, while determining the concentration of the component and the main endpoint before collecting the data. Independent researchers, an appropriate sample size, reproducible imaging and observation after discontinuation would help determine both the magnitude and the durability of any cosmetic benefit.
Interpretation of cosmetic evidence – practical research questions
What does the skin radiance index measure?
Prominence is a characteristic related to appearance, and not a commonly defined biological size.
Various methods can include image analysis, reflection of light from surfaces, color distribution, or the observer’s assessment.
The independent studies cited earlier on the measurement methods show that reproducibility depends on the method and location of the measurement.
Therefore, the percentage change is only relevant when a method and a reference condition have been specified.
The same number cannot be directly converted into a percentage improvement in overall skin health.
Why is a matched control medium important?
The commercial formulation contains a carrier, and the finished cream has its own formulation system.
Comparison with a matched carrier helps determine whether the version containing the active ingredient changes the endpoint more than a similar cream without this ingredient.
An evaluation solely based on the starting value can still describe what happened after the application, but it does not rule out all explanations unrelated to the peptide.
Distinction is particularly important when the hydration itself changes the apparent transparency and radiance of the skin.
How to count multiple experimental reports?
The provider's website, patent, and product brochure may describe the same development experiments.
These are separate documents, but not necessarily separate groups of participants or independent replications.
Abstracts of the evidence should identify the original experiment, its trial, the formulated formulation tested, and the result, then list the supporting documents without artificially inflating the number of studies.
The group of 26 people assessing skin appearance and the group of 29 people in the controlled study should also remain separate.
The additional hydration assessment involving 25 people should not be added to the total number of unique participants without confirmation that there is no overlap between groups.
Research priorities and unresolved questions
A stronger body of evidence should begin with transparent descriptions of the material under study.
In the case of a peptide, this would include the sequence and modifications of the terminal groups.
In the case of a commercial ingredient – the appropriate composition and quality specification.
In the case of a finished product – the formulation and conditions of use.
Without this information, apparent differences between studies may reflect different test materials, rather than reproducible biological effects.
Future cosmetic research would benefit from previously defined endpoints, tailored controls, standardized environmental and imaging conditions, and sufficient reporting of individual variability.
They should distinguish between hydration, surface texture, the uniformity of the skin’s appearance, and wrinkles, rather than combining them into a broad statement about rejuvenation.
Greater diversity in skin tones and independent replication would improve the ability to generalize the results.
Follow-up after cessation of use would be necessary to assess durability, as short-term changes do not confirm a permanent remodeling of the skin.
Mechanistic studies could also examine whether the peptide reaches the appropriate stratum corneum in the conditions of use of the ready-made formulation and whether the proposed differentiation markers mediate the visible effects.
Such work would help to link laboratory observations with results regarding the appearance of skin in humans, without assuming that one automatically explains the other.
Applications
Crystalide is a formulated cosmetic ingredient whose main peptide component is palmitoyl tetrapeptide-10.
The provider's public materials and patent documentation support the research justification and describe the results related to skin appearance.
However, when interpreting the results, it is necessary to retain information about the actual endpoints and control conditions.
The available evidence does not justify transforming a change in the skin appearance index or a cellular marker into a declaration of permanent skin rejuvenation.
The most important thing is to distinguish between the pure peptide, the commercial ingredient, and the finished formulation.
Laboratory studies can support the proposed mechanisms, and cosmetic results in humans can indicate changes in appearance under certain conditions.
However, this does not mean that a lasting reconstruction of the skin has been confirmed, that biological aging has been reversed, or that all products containing Crystalide are equally effective.
Educational, medical and regulatory reservations
The article is of a scientific and educational nature and concerns research into a cosmetic ingredient. It does not constitute a diagnosis, an individual care recommendation, or advice regarding the treatment of skin diseases. The presented evidence does not confirm that Crystalide treats dermatological diseases, reverses biological aging, or causes permanent changes in the skin structure.
The provider’s information and patent documents are not equivalent to independent clinical replication or approval of medical efficacy claims. Tolerability and safety depend on the entire finished formulation, its intended use, and individual factors. Labeling and acceptable cosmetic claims requirements vary among jurisdictions.
References
- Croda Beauty. (n.d.). Crystalide® [Supplier resource]. Retrieved October 23, 2026, from https://www.crodabeauty.com/en-gb/products/product/4146-crystalide
- Mondon, P., Peschard, O., & Leroux, R. (2022). Tetrapeptides, compositions comprising them and their cosmetic use (French Patent Application Publication No. FR3116274A1). https://patents.google.com/patent/FR3116274A1/en
- Mondon, P., Ringenbach, C., & Gracioso, O. (2019). Use of a peptide for the treatment of epiderm (International Patent Application Publication No. WO2019193113A1). https://patents.google.com/patent/WO2019193113A1/en
- Croda Beauty. (n.d.). Clinical study test cream [Supplier resource]. Retrieved October 23, 2026, from https://www.crodabeauty.com/en-gb/formulations/formulation/7722-clinical-study-test-cream
- Petitjean, A., Sainthillier, J. M., Mac-Mary, S., Muret, P., Closs, B., Gharbi, T., & Humbert, P. (2007). Skin radiance: how to quantify? Validation of an optical method. Skin research and technology : official journal of the International Society for Bioengineering and the Skin (ISBS) [and] the International Society for Digital Imaging of Skin (ISDIS) [and] the International Society for Skin Imaging (ISSI), 13(1), 2–8. https://doi.org/10.1111/j.1600-0846.2006.00174.x
- Jiang, Z. X., & DeLaCruz, J. (2011). The benefits of skin moisturization in appearance. Skin research and technology : official journal of the International Society for Bioengineering and the Skin (ISBS) [and] the International Society for Digital Imaging of Skin (ISDIS) [and] the International Society for Skin Imaging (ISSI), 17(1), 51–55. https://doi.org/10.1111/j.1600-0846.2010.00462.x